nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapiprazole—ADRA1A—Endothelin Pathways—ADCY10—nephrolithiasis	0.107	0.107	CbGpPWpGaD
Dapiprazole—ADRA1D—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0605	0.0605	CbGpPWpGaD
Dapiprazole—ADRA1D—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0509	0.0509	CbGpPWpGaD
Dapiprazole—ADRA1B—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0502	0.0502	CbGpPWpGaD
Dapiprazole—ADRA1A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0446	0.0446	CbGpPWpGaD
Dapiprazole—ADRA1B—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0422	0.0422	CbGpPWpGaD
Dapiprazole—ADRA1A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0375	0.0375	CbGpPWpGaD
Dapiprazole—ADRA1D—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.0371	0.0371	CbGpPWpGaD
Dapiprazole—ADRA1B—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.0308	0.0308	CbGpPWpGaD
Dapiprazole—ADRA1A—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.0274	0.0274	CbGpPWpGaD
Dapiprazole—ADRA1D—GPCRs, Other—CHRM3—nephrolithiasis	0.0269	0.0269	CbGpPWpGaD
Dapiprazole—ADRA1D—G alpha (q) signalling events—DGKH—nephrolithiasis	0.0209	0.0209	CbGpPWpGaD
Dapiprazole—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.0187	0.0187	CbGpPWpGaD
Dapiprazole—ADRA1D—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.0181	0.0181	CbGpPWpGaD
Dapiprazole—ADRA1B—G alpha (q) signalling events—DGKH—nephrolithiasis	0.0173	0.0173	CbGpPWpGaD
Dapiprazole—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.0155	0.0155	CbGpPWpGaD
Dapiprazole—ADRA1A—G alpha (q) signalling events—DGKH—nephrolithiasis	0.0154	0.0154	CbGpPWpGaD
Dapiprazole—ADRA1D—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.0151	0.0151	CbGpPWpGaD
Dapiprazole—ADRA1B—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.015	0.015	CbGpPWpGaD
Dapiprazole—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.0138	0.0138	CbGpPWpGaD
Dapiprazole—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.0135	0.0135	CbGpPWpGaD
Dapiprazole—ADRA1A—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.0134	0.0134	CbGpPWpGaD
Dapiprazole—ADRA1B—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.0125	0.0125	CbGpPWpGaD
Dapiprazole—ADRA1D—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.0117	0.0117	CbGpPWpGaD
Dapiprazole—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.0112	0.0112	CbGpPWpGaD
Dapiprazole—ADRA1A—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.0111	0.0111	CbGpPWpGaD
Dapiprazole—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.01	0.01	CbGpPWpGaD
Dapiprazole—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00996	0.00996	CbGpPWpGaD
Dapiprazole—ADRA1B—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00969	0.00969	CbGpPWpGaD
Dapiprazole—ADRA1D—GPCR downstream signaling—RGS14—nephrolithiasis	0.00882	0.00882	CbGpPWpGaD
Dapiprazole—ADRA1A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00861	0.00861	CbGpPWpGaD
Dapiprazole—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00831	0.00831	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling by GPCR—RGS14—nephrolithiasis	0.00801	0.00801	CbGpPWpGaD
Dapiprazole—ADRA1D—GPCR ligand binding—CHRM3—nephrolithiasis	0.00762	0.00762	CbGpPWpGaD
Dapiprazole—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00738	0.00738	CbGpPWpGaD
Dapiprazole—ADRA1B—GPCR downstream signaling—RGS14—nephrolithiasis	0.00732	0.00732	CbGpPWpGaD
Dapiprazole—ADRA1D—GPCR ligand binding—PTH—nephrolithiasis	0.00697	0.00697	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling by GPCR—RGS14—nephrolithiasis	0.00665	0.00665	CbGpPWpGaD
Dapiprazole—ADRA1A—GPCR downstream signaling—RGS14—nephrolithiasis	0.0065	0.0065	CbGpPWpGaD
Dapiprazole—ADRA1B—GPCR ligand binding—CHRM3—nephrolithiasis	0.00632	0.00632	CbGpPWpGaD
Dapiprazole—ADRA1D—GPCR downstream signaling—DGKH—nephrolithiasis	0.00596	0.00596	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling by GPCR—RGS14—nephrolithiasis	0.0059	0.0059	CbGpPWpGaD
Dapiprazole—ADRA1B—GPCR ligand binding—PTH—nephrolithiasis	0.00578	0.00578	CbGpPWpGaD
Dapiprazole—ADRA1A—GPCR ligand binding—CHRM3—nephrolithiasis	0.00562	0.00562	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling Pathways—ADCY10—nephrolithiasis	0.00556	0.00556	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling by GPCR—DGKH—nephrolithiasis	0.00541	0.00541	CbGpPWpGaD
Dapiprazole—ADRA1A—GPCR ligand binding—PTH—nephrolithiasis	0.00514	0.00514	CbGpPWpGaD
Dapiprazole—ADRA1B—GPCR downstream signaling—DGKH—nephrolithiasis	0.00494	0.00494	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling Pathways—RGS14—nephrolithiasis	0.00473	0.00473	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling Pathways—ADCY10—nephrolithiasis	0.00462	0.00462	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling by GPCR—DGKH—nephrolithiasis	0.00449	0.00449	CbGpPWpGaD
Dapiprazole—ADRA1A—GPCR downstream signaling—DGKH—nephrolithiasis	0.00439	0.00439	CbGpPWpGaD
Dapiprazole—ADRA1D—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00431	0.00431	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling Pathways—ADCY10—nephrolithiasis	0.0041	0.0041	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling by GPCR—DGKH—nephrolithiasis	0.00399	0.00399	CbGpPWpGaD
Dapiprazole—ADRA1D—GPCR downstream signaling—PTH—nephrolithiasis	0.00394	0.00394	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling Pathways—RGS14—nephrolithiasis	0.00393	0.00393	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling by GPCR—CHRM3—nephrolithiasis	0.00391	0.00391	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling by GPCR—PTH—nephrolithiasis	0.00358	0.00358	CbGpPWpGaD
Dapiprazole—ADRA1B—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00357	0.00357	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling Pathways—RGS14—nephrolithiasis	0.00349	0.00349	CbGpPWpGaD
Dapiprazole—ADRA1B—GPCR downstream signaling—PTH—nephrolithiasis	0.00327	0.00327	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling by GPCR—CHRM3—nephrolithiasis	0.00325	0.00325	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.0032	0.0032	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling Pathways—DGKH—nephrolithiasis	0.0032	0.0032	CbGpPWpGaD
Dapiprazole—ADRA1A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00317	0.00317	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling by GPCR—PTH—nephrolithiasis	0.00297	0.00297	CbGpPWpGaD
Dapiprazole—ADRA1A—GPCR downstream signaling—PTH—nephrolithiasis	0.0029	0.0029	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling by GPCR—CHRM3—nephrolithiasis	0.00288	0.00288	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling Pathways—DGKH—nephrolithiasis	0.00265	0.00265	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00265	0.00265	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling by GPCR—PTH—nephrolithiasis	0.00264	0.00264	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00236	0.00236	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling Pathways—DGKH—nephrolithiasis	0.00236	0.00236	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling Pathways—CHRM3—nephrolithiasis	0.00231	0.00231	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling Pathways—PTH—nephrolithiasis	0.00211	0.00211	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling Pathways—CHRM3—nephrolithiasis	0.00192	0.00192	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling Pathways—PTH—nephrolithiasis	0.00175	0.00175	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling Pathways—CHRM3—nephrolithiasis	0.0017	0.0017	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling Pathways—PTH—nephrolithiasis	0.00156	0.00156	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling Pathways—SPP1—nephrolithiasis	0.00106	0.00106	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling Pathways—SPP1—nephrolithiasis	0.00088	0.00088	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling Pathways—SPP1—nephrolithiasis	0.000782	0.000782	CbGpPWpGaD
